Why dystrophin quantification is key in the eteplirsen saga

Nat Rev Neurol. 2018 Aug;14(8):454-456. doi: 10.1038/s41582-018-0033-8.
No abstract available

Publication types

  • News

MeSH terms

  • Clinical Trials as Topic
  • Drug Approval
  • Dystrophin / drug effects*
  • Dystrophin / metabolism*
  • Humans
  • Morpholinos / administration & dosage
  • Morpholinos / pharmacology*
  • Muscular Dystrophy, Duchenne / drug therapy*

Substances

  • Dystrophin
  • Morpholinos
  • eteplirsen